Mendus reports positive read-out for first stage VITAL-CML trial
Mendus AB ("Mendus" publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies for myeloid blood cancers, today announced a positive read-out of the first safety and tolerability stage of the VITAL-CML trial, following a review by the Data Safety Monitoring Board (DSMB).VITAL-CML is a p…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.